## Lupin Limited (LUPIN) Stock Analysis - December 20, 2024

This report analyzes the provided data for Lupin Limited (LUPIN) to determine whether it's a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Company Profile:**

| Feature          | Description                               |
|-----------------|-------------------------------------------|
| Symbol           | LUPIN                                    |
| Company Name     | Lupin Limited                             |
| Industry         | Pharmaceuticals                           |
| Listing Date     | September 10, 2001                       |
| ISIN             | INE326A01037                             |


**2. Key Indicators:**

**2.1 Current Price Analysis:**

| Metric             | Value      |
|---------------------|------------|
| Last Price          | 2,149.75   |
| Change             | -13.10     |
| PChange (%)         | -0.61%     |
| Previous Close      | 2,162.85   |
| Open                | 2,165.00   |
| Close               | 2,150.70   |
| VWAP                | 2,161.83   |
| Week High           | 2,312.00   |
| Week Low            | 1,200.15   |
| Sector PE           | 37.21      |
| Symbol PE           | 37.21      |


* The current price shows a slight decrease (-0.61%) compared to the previous close.
* Pre-open activity indicates a slightly lower opening price than the previous close.
* The stock is trading below its week high but significantly above its week low.


**2.2 Financial Performance (Last Five Quarters):**

| Quarter Ending    | Income       | Expenditure  | Profit After Tax | EPS      |
|--------------------|--------------|---------------|--------------------|----------|
| 30-Sep-2024       | 413,882      | 315,477       | 80,776            | 17.71    |
| 30-Jun-2024       | 420,585      | 312,293       | 88,918            | 19.51    |
| 31-Mar-2024       | 342,722      | 299,906       | 38,408            | 8.43     |
| 31-Dec-2023       | 413,891      | 305,495       | 91,644            | 20.14    |
| 30-Sep-2023       | 368,483      | 298,879       | 54,861            | 12.06    |

* Income shows some fluctuation but generally remains above 300,000.
* Profit after tax and EPS show significant variability across quarters.  There's a notable drop in Q3 FY2024.
* Further investigation into the reasons for the fluctuations in profitability is needed.  The detailed financial results notes provide some context (see below).


**2.3 Shareholding Analysis:**

| Quarter Ending    | Promoter & Promoter Group (%) | Public (%) |
|--------------------|-----------------------------|------------|
| 30-Sep-2023       | 47.06                        | 52.94      |
| 31-Dec-2023       | 47.04                        | 52.96      |
| 31-Mar-2024       | 47.01                        | 52.99      |
| 30-Jun-2024       | 46.98                        | 53.02      |
| 30-Sep-2024       | 46.96                        | 53.04      |

* Promoter holdings have shown a slight but consistent decrease over the past year.


**2.4 Corporate Action Summary:**

* **Dividends:**  The company has a history of paying dividends, with the most recent being Rs 8 per share (ex-date 16-Jul-2024).  A detailed dividend history is available in the provided data.


**2.5 Volatility and Risk:**

* **CM Daily Volatility:** 1.67 (This metric needs context; a comparison to industry averages would be beneficial.)
* **CM Annual Volatility:** 31.91 (This metric needs context; a comparison to industry averages would be beneficial.)
* Delivery to Traded Quantity: 49.24% (This suggests a relatively high proportion of delivered trades, indicating some level of long-term investor interest.)


**2.6 Key Directors and Contact Information:**

(A table of key personnel and contact information can be easily constructed from the provided data.  This is omitted for brevity but is straightforward to create.)


**3. Detailed Financial Results Notes (from Q3 FY2024):**

The notes to the financial results highlight several significant events that impacted the Q3 FY2024 results:

* Settlement of a dispute resulting in a one-time gain.
* Transfer of the generic business in India to a subsidiary.
* Transfer of manufacturing sites and R&D operations to another subsidiary.
* Milestone income from AbbVie.
* Impairment charge related to intangibles.
* Dividend payment.

These events significantly impact the interpretation of the financial results and need to be considered when assessing the company's performance.


**4. Recent Announcements:**

Several announcements were made in December 2024, including those related to capital alteration, ESOPs, rumour verification, press releases, and duplicate share certificates.  These require further review to assess their potential impact on the stock price.


**5. Final Verdict:**

**Hold.**

While Lupin Limited shows a history of dividend payments and generally positive income, the significant variability in profitability and EPS across recent quarters, coupled with the substantial corporate actions and restructuring activities, creates uncertainty.  The decrease in promoter holdings also raises some concern.  More information is needed to fully understand the long-term implications of these events before recommending a buy.  A deeper dive into the detailed financial statements and announcements is necessary to make a more confident assessment.  The current data is insufficient to confidently recommend a buy.  Further analysis is required to determine if the current price reflects the underlying value of the company given the recent restructuring and events.
